{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=9", "query": { "condition": "Advanced Stage Solid Tumors", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 3078, "total_pages": 308, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:22:57.821Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05533697", "title": "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "mRNA-4359", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 361, "start_date": "2022-09-01", "completion_date": "2032-02-18", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 16, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05533697" }, { "nct_id": "NCT05234853", "title": "Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "PUR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Purinomia Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2022-04-28", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-01-20", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05234853" }, { "nct_id": "NCT04762602", "title": "A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Isocitrate Dehydrogenase Gene Mutation" ], "interventions": [ { "name": "HMPL-306", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-02-28", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 8, "location_summary": "Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762602" }, { "nct_id": "NCT03192345", "title": "A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Solid Tumor" ], "interventions": [ { "name": "SAR439459", "type": "BIOLOGICAL" }, { "name": "Cemiplimab REGN2810", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2017-06-09", "completion_date": "2022-01-17", "has_results": false, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 6, "location_summary": "Fairway, Kansas • Boston, Massachusetts • Durham, North Carolina + 2 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03192345" }, { "nct_id": "NCT05625412", "title": "A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986360", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-12-09", "completion_date": "2025-05-12", "has_results": false, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 8, "location_summary": "Los Angeles, California • New Orleans, Louisiana • Hackensack, New Jersey + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625412" }, { "nct_id": "NCT05277051", "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Remzistotug", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "GSK5764227", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2022-03-22", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 7, "location_summary": "San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277051" }, { "nct_id": "NCT07909031", "title": "CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Gastric/GEJ", "Biliary Tract Cancer (BTC)", "Esophageal Squamous Cell Carcinoma (ESCC)", "Ovarian Cancer", "Endometrial Cancer", "Cervical Cancer Metastatic", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CR-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crescent Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2026-10-21", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 3, "location_summary": "Austin, Texas • Dallas, Texas • Fairfax, Virginia", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07909031" }, { "nct_id": "NCT04439253", "title": "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-08-12", "completion_date": "2027-03-17", "has_results": true, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439253" }, { "nct_id": "NCT07897799", "title": "The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases From Solid Tumors" ], "interventions": [ { "name": "Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "T-MAXIMUM Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2027-12-30", "completion_date": "2030-12-20", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07897799" }, { "nct_id": "NCT04618393", "title": "A Study of EMB-02 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "EMB-02", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Shanghai EpimAb Biotherapeutics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-03-11", "completion_date": "2024-03-21", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-11-15T12:22:57.821Z", "location_count": 2, "location_summary": "Colorado Springs, Colorado • Greenville, South Carolina", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04618393" } ] }